These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 594841)

  • 21. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
    Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of rubella during an epidemic on Taiwan. HPV-77 and RA 27-3 rubella vaccines administered subcutaneously and intranasally HPV-77 vaccine mixed with mumps and-or measles vaccines.
    Beasley RP; Detels R; Kim KS; Gale JL; Lin TL; Grayston JT
    Am J Dis Child; 1969 Aug; 118(2):301-6. PubMed ID: 4893832
    [No Abstract]   [Full Text] [Related]  

  • 23. [Measles-rubella vaccination campaign].
    Infirm Fr; 1984 Jan; (251):23-6. PubMed ID: 6561159
    [No Abstract]   [Full Text] [Related]  

  • 24. [Measles and rubella].
    Takayama N
    Rinsho Byori; 2005 Sep; 53(9):845-52. PubMed ID: 16235838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progress in measles and rubella elimination in Iran.
    Esteghamati A; Gouya MM; Zahraei SM; Dadras MN; Rashidi A; Mahoney F
    Pediatr Infect Dis J; 2007 Dec; 26(12):1137-41. PubMed ID: 18043452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Control of measles and rubella through use of attenuated vaccines.
    Meyer HM; Hopps HE; Parkman PD; Ennis FA
    Am J Clin Pathol; 1978 Jul; 70(1 Suppl):128-35. PubMed ID: 685885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The strategy for prevention of measles and rubella prevalence with measles-rubella (MR) vaccine in Japan.
    Ihara T
    Vaccine; 2009 May; 27(24):3234-6. PubMed ID: 19366578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The clinico-immunological evaluation of a bivalent vaccine against measles and rubella].
    Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G
    Minerva Pediatr; 1990 Dec; 42(12):531-6. PubMed ID: 2087226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topics in clinical medicine. New vaccines against viral diseases: mumps, rubella, and measles.
    Seto DS; Carver DH
    Johns Hopkins Med J; 1969 Apr; 124(4):231-7. PubMed ID: 5774148
    [No Abstract]   [Full Text] [Related]  

  • 30. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis.
    Flynn JT; Frisch K; Kershaw DB; Sedman AB; Bunchman TE
    Adv Perit Dial; 1999; 15():269-72. PubMed ID: 10682116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of mumps virus given alone or in combination with live vaccines against measles and rubella.
    Nasibov MN; Yakovleva NV; Smorodintsev AA
    Prog Immunobiol Stand; 1970; 4():676-82. PubMed ID: 5482205
    [No Abstract]   [Full Text] [Related]  

  • 32. [Vaccination rate for triple measles-rubella-mumps vaccine in Empoli Val d'Elsa area health district U.S.L. 11, Tuscany Region].
    Salvadori P
    Ann Ig; 1998; 10(1):19-24. PubMed ID: 9616974
    [No Abstract]   [Full Text] [Related]  

  • 33. [Tuberculin allergy and behavior of leukocytes in tuberculin-positive children vaccinated against rubella].
    Businco L; Moschini L; Midulla M
    Minerva Pediatr; 1971 Mar; 23(9):371-4. PubMed ID: 5314024
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost effectiveness of prevaccination screening of health care workers for immunity to measles, rubella and mumps.
    Ferson MJ; Robertson PW; Whybin LR
    Med J Aust; 1994 Apr; 160(8):478-82. PubMed ID: 8170422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [What is the present status of the common virus vaccines?].
    Regnard J
    Nouv Presse Med; 1972 Jan; 1(1):33-8. PubMed ID: 5061188
    [No Abstract]   [Full Text] [Related]  

  • 36. [Side effects of the use of the preventive mixed mumps, rubella and measles vaccine inchildren of the City of São Paulo].
    Konichi SR; Laus WC; Mattos CA; Amato Neto V; Aly J; Finger H; Bianchi A
    Rev Inst Med Trop Sao Paulo; 1973; 15(3):161-4. PubMed ID: 4732747
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunogenicity and reactogenicity of indigenously produced MMR vaccine.
    Bhargava I; Chhaparwal BC; Phadke MA; Irani SF; Chhaparwal D; Dhorje S; Maheshwari CP
    Indian Pediatr; 1995 Sep; 32(9):983-8. PubMed ID: 8935261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines.
    Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Pediatrics; 1975 Sep; 56(3):380-7. PubMed ID: 1161394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The national measles and rubella campaign--one year on.
    Commun Dis Rep CDR Wkly; 1995 Nov; 5(45):237. PubMed ID: 8541943
    [No Abstract]   [Full Text] [Related]  

  • 40. The timing of tuberculin tests in relation to immunization with live viral vaccines.
    Brickman HF; Beaudry PH; Marks MI
    Pediatrics; 1975 Mar; 55(3):392-6. PubMed ID: 1143978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.